p53 antibody (AA 32-79)

Catalog No. ABIN5646914

This anti-p53 antibody is a Mouse Monoclonal antibody detecting p53 in WB, IF, FACS and IHC (p). Suitable for Human.

Quick Overview for p53 antibody (AA 32-79) (ABIN5646914)

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This p53 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: PAb 1801

Product Details anti-p53 Antibody

Binding Specificity: AA 32-79

No Cross-Reactivity: Mouse (Murine), Rat (Rattus)

Characteristics: This mAb reacts with an N-terminal epitope (aa 32-79) of both wild type and mutated p53. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. If it occurs in the germ line, such tumors run in families. In most transformed and tumor cells the concentration of p53 is increased 5-1000 fold over the minute concentrations (1000 Molecules cell) in normal cells, principally due to the increased half-life (4 h) compared to that of the wild-type (20 min). It localizes in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution. Mutations arise with an average frequency of 70 % but incidence varies from zero in carcinoid lung tumors to 97 % in primary melanomas. High concentrations of p53 protein are transiently expressed in human epidermis and superficial dermal fibroblasts following mild ultraviolet irradiation. Positive nuclear staining with specific antibody has been reported to be a negative prognostic factor in breast carcinoma, lung carcinoma, colorectal, and urothelial carcinoma. Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma as well as to detect intratubular germ cell neoplasia.

Purification: Purified

Purity: Protein G affinity chromatography

Immunogen: Human p53 beta-galactosidase fusion protein was used as the immunogen for this antibody. Its epitope maps near the N-terminal end (aa 32-79) of p53.

Isotype: IgG1 kappa

Application Details

Application Notes: Variations in protocols, secondaries and substrates may require the p53 antibody to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 0.5-1 μg/mL,FACS: 0.5-1 μg/million cells,Immunofluorescence: 1-2 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the p53 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for p53

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Alternative Name: p53 / TP53

Background: This mAb reacts with an N-terminal epitope (aa 32-79) of both wild type and mutated p53. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. If it occurs in the germ line, such tumors run in families. In most transformed and tumor cells the concentration of p53 is increased 5-1000 fold over the minute concentrations (1000 Molecules cell) in normal cells, principally due to the increased half-life (4 h) compared to that of the wild-type (20 min). It localizes in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution. Mutations arise with an average frequency of 70 % but incidence varies from zero in carcinoid lung tumors to 97 % in primary melanomas. High concentrations of p53 protein are transiently expressed in human epidermis and superficial dermal fibroblasts following mild ultraviolet irradiation. Positive nuclear staining with specific antibody has been reported to be a negative prognostic factor in breast carcinoma, lung carcinoma, colorectal, and urothelial carcinoma. Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma as well as to detect intratubular germ cell neoplasia.

Pathways: p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling, Chromatin Binding, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Autophagy, Warburg Effect